Recently added Catalysts

PF-04360365

Phase 2

Alzheimer's Disease | Monoclonal antibody | Neurology |Pfizer, Inc.|Last Updated: Apr 19, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC

Total Trials7

Total Enrollment331

FDA Designations

No designations recorded

Clinical trial landscape

PF-04360365 · 7 trials · 1 indication

Phase 2 2Phase 1 5

NCT00945672A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's Disease

COMPLETED36 Analytics

NCT00722046Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's DiseaseAlzheimer's Disease

COMPLETED198 Analytics

PHASE2COMPLETED

A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

NCT0094567236

Unlock trial analytics

PHASE2COMPLETED

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

NCT00722046198

Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

Day 1 up to 6 months after last dose of study medication (up to 18 months)

An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. SAE: an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study medication and up to 6 months after last dose (up to 18 months) that were absent before treatment or worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

Number of Participants With Change From Baseline in Brain Magnetic Resonance Imaging (MRI) Abnormalities

Baseline up to Month 18

Number of participants with new clinical findings not evident on the baseline scans, such as brain edema, hemorrhage, encephalitis and other pathology (cerebral edema, cerebral/meningeal enhancement, micro hemorrhage, parenchymal hematoma, subarachnoid hemorrhage, subdural hematoma, cortical infarcts, subcortical grey matter infarcts, white matter infarcts and white matter hyper intensities) were assessed from structural magnetic resonance imaging (MRI). Participants with brain abnormality other than those listed above assessed using MRI scan were reported under 'other' category. Only those MRI findings in which at least 1 participant had event, were reported.

Number of Participants With Gadolinium Use in Brain Magnetic Resonance Imaging (MRI)

Baseline up to Month 18

Brain MRI included gadolinium contrast if investigator determined this was necessary for participant care either based on clinical signs or the non-contrast MRI. This decision was made by the investigator on the basis of change in the clinical examination or in response to a possible abnormality seen on the non-contrast brain MRI.

Change From Baseline in Amyloid Load at Month 13 Using Positron Emission Tomography (PET) Technique: Cohort M

Baseline, Month 13

Quantitative amyloid imaging was performed using PET technique using \[11C\] Pittsburgh Compound B (PIB) for following brain areas: frontal, temporal, parietal and occipital cortices, anterior and posterior cingular cortex, cerebellum, pons, and subcortical white matter. For target regions of interest, beta-amyloid plaque imaging radiotracer (PIB) retention data was expressed as standard uptake value ratio (SUVR) which was defined as a ratio of radioactivity uptake of the target region relative to the cerebellum reference region. This outcome measure was planned to be analyzed only for cohort M.

Mean Cerebrospinal Fluid (CSF) Concentration of PF-04360365 at 0 Hour on Day 0

0 hour on Day 0 (Day prior to dosing)